ALGESAL Cream (2020)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Algesal.
Qualitative and quantitative composition
Each tube of Algesal contains Diethylamine Salicylate 10%w/w. <u>Excipient(s) with known effects:</u> Lavandin composition (Contains d-limonene & Linalool) 0.10% w/w. For a full list of excipients see ...
Pharmaceutical form
Off white, lavender-scented cream.
Therapeutic indications
For symptomatic relief of rheumatic and minor musculo-skeletal conditions including lumbago, fibrositis, sciatica, bruises and strains.
Posology and method of administration
Adults (including the elderly) and children 6 years and over For cutaneous use. Apply three times daily to the affected area, massaging until cream is fully absorbed. Children under 6 years Not recommended. ...
Contraindications
Hypersensitivity to the active substances or to any of the excipients. Algesal should not be used if the surface of the skin is broken. Algesal contains terpene derivatives (ie camphor) as excipients, ...
Special warnings and precautions for use
Consult your doctor before use if you are pregnant, breastfeeding, asthmatic or on any other medicines. For external use only. Not to be used on broken skin. Avoid contact with eyes and sensitive areas ...
Interaction with other medicinal products and other forms of interaction
There have been reports that topical salicylates may potentiate the anticoagulant effects of warfarin. It is therefore advisable that caution should be exercised with patients who are on coumarin anticoagulants. ...
Pregnancy and lactation
Pregnancy There is inadequate evidence of safety in human pregnancy, Algesal should not be used in pregnancy unless there is no safer alternative. Lactation Not recommended.
Effects on ability to drive and use machines
Not applicable.
Undesirable effects
Temporary skin reactions (redness, burning sensation and rashes) may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is ...
Overdose
Overdose is unlikely when used as recommended. If applied to a large area of skin, or in the unlikely event of oral ingestion, the product may cause systemic adverse effects depending on the amount absorbed. ...
Pharmacodynamic properties
Diethylamine salicylate is a topical analgesic, with the anti-inflammatory properties of salicylates.
Pharmacokinetic properties
After topical application small amounts of salicylic acid are detectable in the plasma. Elimination in the urine occurs over a period of 48 hours.
Preclinical safety data
There are no additional preclinical safety data of relevance to the prescriber.
List of excipients
Ethylene glycol stearate Glycerol monostearate Stearic acid Triethanolamine Petrolatum Light liquid paraffin Microcrystalline wax Lavandin composition Purified water
Incompatibilities
Not known.
Shelf life
5 years.
Special precautions for storage
Do not store above 25°C.
Nature and contents of container
50g: Aluminium tube with a white HDPE screw cap. 100g: Aluminium tube with a white HDPE screw cap.
Special precautions for disposal and other handling
Wash hands well after use.
Marketing authorization holder
Thornton & Ross Limited, Linthwaite, Huddersfield, HD7 5QH, United Kingdom
Marketing authorization number(s)
PL 00240/0342
Date of first authorization / renewal of the authorization
21/02/2006
Date of revision of the text
29/09/2020
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
